Quality of Botulinum Toxin for Human Treatment

  • Edward J. Schantz
  • Eric A. Johnson


The crystallized botulinum toxin type A now used in treatment, Batch 79-11 prepared in November 1979 and licensed as an Orphan drug by the FDA in December 1989, has served well for treatment of many human dystonias and other involuntary muscle movement disorders. The continued production of high quality botulinum toxin presents some important problems that must be investigated. In this presentation we wish to make some proposals that should improve the quality of the toxin as a pharmaceutical.


Botulinum Toxin Orphan Drug Botulinum Toxin Type Clostridium Botulinum Spasmodic Torticollis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992; 56: 80–99.PubMedGoogle Scholar
  2. 2.
    Patterson-Curtis S, Johnson EA. Regulation of neurotoxin and protease formation in Clostridium botulinum Okra B and Hall A by arginine. Appl Environ Microbiol 1989; 55: 1544–1548.Google Scholar
  3. 3.
    Schantz EJ, Kautter DA. Standardized assay for Clostridium botulinum toxins. J Assoc Off Anal 1978; 61: 96–99.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Edward J. Schantz
    • 1
  • Eric A. Johnson
    • 1
  1. 1.Food Research InstituteUniversity of WisconsinMadisonUSA

Personalised recommendations